AHA 2020 | Omega-3 Fatty Acids Provide No Cardiovascular Benefits and Cause More Atrial Fibrillation

Results confirm the interim analysis, whereby the study was suspended for futility. Omega-3 fatty acids do not reduce cardiovascular events in patients with high triglycerides and low HDL.

Previous studies, such as REDUCE-IT, had shown positive results, but given this new research (presented at the American Heart Association [AHA] 2020 Congress and simultaneously published in JAMA), we need to come to terms with the fact that omega-3 fatty acids provide no benefit.

The problem in REDUCE-IT was that the control arm received mineral oil. That has a pro-inflammatory effect: it increases LDL, apolipoprotein B, and C reactive protein. All of that supported the interpretation that the differences between treatment arms were linked to the benefit derived from omega 3 acids, when they were probably due to the adverse events in the control group.

However, in the STRENGTH study, the control arm used corn oil, which has a neutral effect.

The study included 13,078 patients under statin treatment, presenting high risk for cardiovascular events, with high triglycerides (180 to 500 mg/dl), and low HDL (<42 mg/dl in males and <47 mg/dl in women).


Read also: AHA 2020 | RIVER: Rivaroxaban as Alternative to Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Mitral Valve.


Participants were randomized to corn oil or omega 3 fatty acids (such as eicosapentaenoic acid and docosahexaenoic acid).

At a mean 42 months of follow-up, omega 3 fatty acids did not reduce cardiovascular death, infarction, coronary revascularization, or hospitalization for unstable angina (12.0% vs. 12.2%; hazard ratio [HR]: 0.99; 95% confidence interval [CI]: 0.90-1.09).

There was an increased risk for new atrial fibrillation (2.2% vs. 1.3%; HR: 1.69; 95% CI: 1.29-2.21) with omega 3, which is consistent with the results of REDUCE-IT.

STRENGTH

Original Title: Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial.

Reference: Nicholls SJ et al. JAMA. 2020; Epub ahead of print y presentado en el congreso AHA 2020.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

AHA 2025 | DAPT-MVD: Extended DAPT vs. Aspirin Monotherapy After PCI in Multivessel Disease

In patients with multivessel coronary artery disease who remain stable 12 months after drug-eluting stent (DES) stenting, there is uncertainty as to prolonging dual...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....